What Modern Hormone Research Actually Says About Perimenopause

A research-grounded guide to the seven-to-ten-year transition that most women weren’t told was coming, what’s actually happening in the body, and where the science is now pointing.

---

The story most women were told about menopause goes something like this. Sometime in your early fifties, your periods stop. You may experience hot flashes for a few years. Hormone replacement therapy is an option, with caveats. After menopause, you’re postmenopausal, and that chapter is closed.

This story is mostly wrong.

The actual research, accumulated over the last three decades and still expanding, describes something both more complicated and more interesting. Menopause is not a phase. It is a single moment, defined as the date marking twelve months without a menstrual period. The transition that surrounds it, the part with the symptoms, the hormonal turbulence, and the cellular changes, has its own name: perimenopause. It begins seven to ten years before the final menstrual period and continues for one full year after it.[^1]

That means perimenopause for the average woman starts not in her early fifties, but in her early forties. Sometimes earlier. And it lasts, by current scientific definition, for the better part of a decade.

This is the piece most women weren’t given before they needed it. It walks through what perimenopause actually is, how the science has come to define it, what the research documents about its symptoms (which extend well beyond hot flashes), and where modern peptide research is starting to intersect with the cellular biology underneath the experience.

The transition science has actually defined

Until relatively recently, “perimenopause” was a loose term used inconsistently across medical literature. In 2001, a working group of researchers met in Park City, Utah, to standardize the terminology. The result was the Stages of Reproductive Aging Workshop, known in the literature as STRAW, with an updated framework called STRAW+10 published in 2012.[^2]

STRAW+10 divides a woman’s reproductive life into ten stages, anchored to the final menstrual period (FMP) as the reference point. The transition relevant to most midlife women includes:

Late Reproductive Stage (Stage -3) The years immediately before perimenopause. Cycles are still mostly regular, but subtle hormonal shifts have begun. Anti-Müllerian hormone levels start declining. Some women notice early changes in cycle length or premenstrual symptoms.

Early Menopausal Transition (Stage -2) The first official stage of perimenopause. Defined by persistent variation in cycle length of seven days or more. Hormones begin fluctuating more dramatically. For the average woman, this stage begins around age 47.[^3]

Late Menopausal Transition (Stage -1) Cycles become more disrupted, with periods of amenorrhea lasting 60 days or longer. Estrogen levels drop more steeply, and the most intense symptoms typically emerge during this phase. Average age of entry: 49.

Final Menstrual Period (FMP) The actual moment of menopause. Median age in U.S. women: 51.4 years.[^4]

Early Postmenopause (Stages +1a, +1b) The first six years after the final period, during which symptoms often continue and the most rapid changes in bone density, skin, and cardiovascular risk occur.

The piece that catches most women off guard is the duration. Perimenopause is not a brief preamble to menopause. It is, on average, a seven-to-ten-year transition during which the body undergoes profound and continuous change. Some women move through it more quickly. Some women experience it for longer. The variability is wide enough that a one-size-fits-all timeline is misleading.

The largest study you’ve never heard of

For most of medical history, perimenopause was understudied because the women going through it were understudied. That began to change in 1995, when the National Institutes of Health funded an ambitious longitudinal cohort study called the Study of Women’s Health Across the Nation, abbreviated as SWAN.[^5]

SWAN enrolled 3,302 women aged 42 to 52 across seven U.S. sites, with deliberate inclusion of multiple racial and ethnic groups. The women were followed prospectively, in some cases for up to 22 years, with annual measurements of hormones, symptoms, body composition, mood, cognition, sleep, and cardiovascular markers.

It is the most comprehensive characterization of the perimenopausal transition ever conducted, and many of the things modern research now considers established about perimenopause come directly from its findings.

A few of those findings are worth pausing on, because they overturn what women have long been told.

What the data actually showed

Vasomotor symptoms last much longer than anyone thought.

The medical conventional wisdom for decades held that hot flashes and night sweats lasted “a few years.” SWAN data showed something different. Up to 80% of women in the study reported vasomotor symptoms during the transition, and the median duration of frequent symptoms was 7.4 years.[^6] For some women, symptoms persisted for more than a decade. Black women in the cohort tended to experience longer symptom durations than other groups. The duration is not a few years. For the average woman, it is most of a decade.

Symptoms are not just vasomotor.

A 2018 SWAN analysis tracked 58 different symptoms across the transition.[^7] Beyond the well-known categories (hot flashes, night sweats, irregular periods), women consistently reported sleep disturbance, mood changes, joint and muscle pain, brain fog and memory difficulties, increased anxiety, vaginal dryness, urinary changes, weight redistribution, and fatigue.

The clustering of these symptoms is part of what makes perimenopause confusing. Each symptom in isolation looks like something else. Brain fog could be stress. Joint pain could be arthritis. Mood changes could be depression. Fatigue could be anything. Looked at together, against the backdrop of perimenopausal age, they form a pattern. But women rarely encounter that pattern because they encounter each symptom individually, often with separate clinicians treating each one as an unrelated problem.

Mood and cognition are real, measurable, and not “in your head.”

SWAN’s mood and cognition findings have been particularly important. The risk of clinically significant depressive symptoms increases meaningfully during late perimenopause, with abrupt elevation in prevalence as women approach the final menstrual period.[^8] Cognitive testing across the cohort documented genuine reductions in cognitive processing speed and verbal memory during the transition, independent of mood and sleep symptoms. The “perimenopause brain fog” that women describe is not subjective. It is measurable on cognitive testing.[^9]

Cardiovascular risk shifts during the transition, not after it.

For decades, cardiovascular disease in women was framed as a postmenopausal concern. SWAN data, with its long follow-up period, documented that the cardiovascular risk profile begins shifting during perimenopause: cholesterol patterns change, vascular function alters, and the trajectory toward later CVD events is set in motion well before menopause itself.[^10] Vasomotor symptoms have themselves been linked to subsequent cardiovascular events. Hot flashes are not just uncomfortable. In the longest follow-up data, they were associated with later cardiac risk.

The hormonal mechanics underneath

The reason perimenopausal symptoms cluster the way they do is rooted in what estrogen has been doing in the body all along. Estrogen is not only a reproductive hormone. It is a metabolic regulator with effects on essentially every major system: brain, bone, skin, cardiovascular, mitochondrial, and immune.

When estrogen levels become erratic during the transition, then decline more steeply in late perimenopause, the consequences appear wherever estrogen had been quietly maintaining function. The brain feels it. The skin feels it. The mitochondria feel it. The bones, the blood vessels, the gut microbiome, and the inflammatory regulatory system all feel it.

This is why no single intervention addresses the whole picture. A topical retinoid does something for skin. Strength training does something for bones. Cognitive behavioral therapy does something for sleep. A clinician-supervised approach to hormone therapy does something for symptoms broadly, when appropriate. But the underlying transition is happening at the cellular level, across multiple systems at once, and the most useful framework for understanding it is to recognize that perimenopause is not one problem. It is a coordinated shift in how the entire body operates.

NextSelf Labs has written separately about two specific consequences of this shift:

• What happens to skin. The estrogen-mediated decline in dermal fibroblast function and collagen synthesis is the cellular biology underneath what women see in the mirror through their forties and beyond. We covered this in What Actually Happens to Your Skin After 30, including the foundational Brincat 1987 finding that women lose approximately 30% of dermal collagen in the first five years after menopause.
• What happens to energy. The mitochondrial dysfunction that emerges during perimenopause, driven by estrogen’s loss of regulatory effect on cellular energy production, is the subject of Why Your Energy Stopped Behaving in Your Forties, including the foundational research from the Brinton lab on the perimenopausal bioenergetic transition.

Both pieces describe one specific consequence of the broader hormonal shift this article is about.

Where the research is now pointing

If perimenopause is a coordinated multi-system transition, the most interesting new research is the work that takes that complexity seriously. Three areas are particularly active:

Hormone therapy reconsidered. The decades-long medical avoidance of hormone replacement therapy, triggered by the 2002 Women’s Health Initiative findings, has been substantially revised since. Modern research and updated clinical guidelines distinguish between starting hormone therapy near the onset of menopause (which appears to carry meaningfully different risks than starting it later) and the formulations and doses available now versus those used in the original WHI cohort. The current state of the research, as reflected in updated guidelines from the Menopause Society and major endocrine societies, is more nuanced than the cautionary headlines from twenty years ago suggested. Conversations with informed clinicians who specialize in midlife hormonal health have become substantially more useful than they were a decade ago.

Mitochondrial-derived peptides. The discovery in 2015 of MOTS-c, a peptide encoded by mitochondrial DNA itself, opened a new field of research into how mitochondria communicate with the rest of the cell, particularly under metabolic stress.[^11] One 2019 study by Lu and colleagues, published in the Journal of Molecular Medicine, examined MOTS-c specifically in ovariectomized mice (a standard model for postmenopausal hormonal change) and documented prevention of the obesity and insulin resistance that typically follow estrogen loss.[^12] Other research on SS-31 (elamipretide), a peptide that selectively concentrates in mitochondria, has documented effects on cellular energy production and mitochondrial integrity in aging models.[^13] These are early studies. The translation to human women in midlife requires the careful caveats that any responsible reading of preclinical research demands. But these are also among the first peptide research programs that engaged seriously with the metabolic question women in perimenopause are asking, in models designed to mimic the hormonal transition.

Kisspeptin and the reproductive axis. Kisspeptin, the peptide that effectively starts puberty by signaling the hypothalamus to release reproductive hormones, has emerged as one of the most-studied molecules in modern reproductive endocrinology.[^14] Its role in the reproductive cycle is foundational, and current research is exploring its connections to mood, libido, and the broader experience of perimenopausal transition.

Multi-pathway thinking. The scientific shift that matters most is conceptual. The old framework treated perimenopausal symptoms as separate problems to be addressed by separate clinicians. The new framework recognizes that the symptoms cluster because the underlying biology is connected. Mood and sleep and cognition and energy and metabolism are not separate stories. They are different views of the same hormonal transition, and the most useful interventions are the ones that address that underlying biology directly.

What this changes about how to think about your own transition

The most useful thing the modern research has done is name what’s happening.

A woman in her early forties experiencing the cluster of symptoms described above is not failing at being healthy. She is not depressed in the conventional sense. She is not losing her mind. She is not becoming the person she’ll be at 70. She is in the middle of one of the most significant biological transitions of her life, a transition that medical science has only recently begun to characterize in the depth it deserves, and one that her mother and grandmother almost certainly went through without ever being told what was happening.

The implications of this are practical:

Find a clinician who actually understands perimenopause. Most general practitioners were trained in a framework that has been substantially revised. Functional medicine and integrative medicine clinicians, certified menopause practitioners (the Menopause Society maintains a directory), and reproductive endocrinologists who specialize in midlife are typically more current. The conversation worth having is broader than “do I need HRT.” It includes hormonal evaluation, cardiovascular risk assessment, bone density baselines, metabolic markers, and sleep evaluation.

Track what’s actually changing. Keeping a basic log of symptoms, cycle changes, and how you’re feeling over the course of months produces the most useful diagnostic data your clinician can have. Memory of “feeling off” is less useful than written observations across a year.

Be honest about what’s happening. Many of the symptoms women experience during perimenopause are dismissed (by themselves, their families, and sometimes their doctors) as stress, or aging, or “just life.” They are usually, in reality, perimenopause. Naming it matters because it changes which questions you ask and which interventions you consider.

Take the seven-to-ten-year framing seriously. The investments made early in the transition, in bone density, cardiovascular health, sleep architecture, muscle mass, and metabolic resilience, compound over the duration of the transition and beyond. The choices made at 42 are not separable from how you feel at 52.

NextSelf Labs offers a small set of research peptides whose roles intersect with the biology described in this piece, including MOTS-c, SS-31, and Kisspeptin, among others. They are sold as research chemicals for laboratory use. The catalog is built around the proposition that women considering peptides deserve to know what the research actually shows, and where the gaps still are. For more on what we mean by that, you can read our essay on the peptide research women were left out of.

The transition is not optional. The version of it you have, with what knowledge and which support, is.

---

References

[^1]: Harlow, S. D., Gass, M., Hall, J. E., Lobo, R., Maki, P., Rebar, R. W., Sherman, S., Sluss, P. M., & de Villiers, T. J. (2012). “Executive summary of the Stages of Reproductive Aging Workshop +10: addressing the unfinished agenda of staging reproductive aging.” Journal of Clinical Endocrinology & Metabolism, 97(4), 1159 to 1168. PMC3340903. The STRAW+10 framework defines perimenopause as beginning approximately seven to ten years before the final menstrual period and continuing for twelve months after it.

[^2]: Soules, M. R., Sherman, S., Parrott, E., Rebar, R., Santoro, N., Utian, W., & Woods, N. (2001). “Executive summary: Stages of Reproductive Aging Workshop (STRAW).” Fertility and Sterility, 76(5), 874 to 878. The original STRAW consensus document.

[^3]: Santoro, N. (2016). “Perimenopause: From Research to Practice.” Journal of Women’s Health, 25(4), 332 to 339. PMC4834516. Documents average ages of entry into early and late menopausal transition stages.

[^4]: El Khoudary, S. R., Greendale, G., Crawford, S. L., Avis, N. E., Brooks, M. M., Thurston, R. C., Karvonen-Gutierrez, C., Waetjen, L. E., & Matthews, K. (2019). “The menopause transition and women’s health at midlife: a progress report from the Study of Women’s Health Across the Nation (SWAN).” Menopause, 26(10), 1213 to 1227. PMC6784846. Documents median age of natural menopause at 51.4 years across the SWAN cohort.

[^5]: Sowers, M., Crawford, S. L., Sternfeld, B., Morganstein, D., Gold, E. B., Greendale, G. A., et al. (2000). “SWAN: A multicenter, multiethnic, community-based cohort study of women and the menopausal transition.” In Menopause: Biology and Pathobiology. Academic Press. The original SWAN study design publication.

[^6]: Avis, N. E., Crawford, S. L., Greendale, G., Bromberger, J. T., Everson-Rose, S. A., Gold, E. B., Hess, R., Joffe, H., Kravitz, H. M., Tepper, P. G., & Thurston, R. C. (2015). “Duration of menopausal vasomotor symptoms over the menopause transition.” JAMA Internal Medicine, 175(4), 531 to 539. The 7.4-year median duration of frequent VMS finding from SWAN.

[^7]: Harlow, S. D., Karvonen-Gutierrez, C., Elliott, M. R., Bondarenko, I., Avis, N. E., Bromberger, J. T., Brooks, M. M., Miller, J. M., & Reed, B. D. (2017). “It is not just menopause: symptom clustering in the Study of Women’s Health Across the Nation.” Women’s Midlife Health, 3, 2. PMC5760187. The 58-symptom analysis demonstrating the breadth of perimenopausal symptom clusters.

[^8]: Bromberger, J. T., & Kravitz, H. M. (2011). “Mood and Menopause: Findings from the Study of Women’s Health Across the Nation (SWAN) over ten years.” Obstetrics and Gynecology Clinics of North America, 38(3), 609 to 625. PMC3197240. Documents elevated risk of clinically significant depressive symptoms during late perimenopause.

[^9]: Greendale, G. A., Karlamangla, A. S., & Maki, P. M. (2020). “The Menopause Transition and Cognition.” JAMA, 323(15), 1495 to 1496. Synthesizes SWAN findings on cognitive changes during the transition.

[^10]: Thurston, R. C., et al. (2021). “Menopausal Vasomotor Symptoms and Risk of Incident Cardiovascular Disease Events in SWAN.” Journal of the American Heart Association, 10(3). JAHA Journal. Twenty-two-year follow-up on cardiovascular outcomes in the SWAN cohort.

[^11]: Lee, C., Zeng, J., Drew, B. G., Sallam, T., Martin-Montalvo, A., Wan, J., Kim, S. J., Mehta, H., Hevener, A. L., de Cabo, R., et al. (2015). “The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance.” Cell Metabolism, 21(3), 443 to 454. The foundational paper introducing MOTS-c.

[^12]: Lu, H., Tang, S., Xue, C., Liu, Y., Wang, J., Zhang, W., Luo, W., & Chen, J. (2019). “Mitochondrial-Derived Peptide MOTS-c Increases Adipose Thermogenic Activation to Promote Cold Adaptation.” Journal of Molecular Medicine, 97(7), 1004 to 1015. PubMed: 30725119. Includes ovariectomized mouse model relevant to postmenopausal hormonal change.

[^13]: Szeto, H. H. (2014). “First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics.” British Journal of Pharmacology, 171(8), 2029 to 2050. Foundational paper on SS-31 (elamipretide) mechanism of action.

[^14]: Skorupskaite, K., George, J. T., & Anderson, R. A. (2014). “The kisspeptin-GnRH pathway in human reproductive health and disease.” Human Reproduction Update, 20(4), 485 to 500. Comprehensive review of kisspeptin’s role in the reproductive axis.

---

This piece reflects the views of NextSelf Labs and is intended for educational purposes. NextSelf Labs sells research peptides for laboratory use only. Products are not intended for human consumption, therapeutic use, or diagnostic application. Information presented here should not be construed as medical advice. Consult a qualified healthcare provider for any decisions regarding personal health, including hormone therapies, perimenopause management, and decisions about hormone replacement.